GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating restated by JPMorgan Chase & Co. in a report released on Thursday, Marketbeat reports.
Several other research analysts have also recently weighed in on GSK. Citigroup restated a “neutral” rating and set a GBX 1,700 ($22.23) target price on shares of GSK in a report on Monday, June 26th. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Friday, June 16th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,730 ($22.62) target price on shares of GSK in a research report on Monday, June 5th. Jefferies Financial Group reiterated a “hold” rating and set a GBX 1,575 ($20.59) target price on shares of GSK in a research note on Monday, June 26th. Finally, Bank of America lowered their target price on shares of GSK from GBX 1,450 ($18.96) to GBX 1,390 ($18.17) in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of GBX 1,570 ($20.53).
GSK Stock Up 0.1 %
Shares of LON GSK opened at GBX 1,388.20 ($18.15) on Thursday. The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 184.80. The stock has a market capitalization of £56.78 billion, a PE ratio of 1,239.46, a price-to-earnings-growth ratio of 1.29 and a beta of 0.31. The stock’s fifty day simple moving average is GBX 1,378.06 and its two-hundred day simple moving average is GBX 1,422.71. GSK has a 12-month low of GBX 1,280.92 ($16.75) and a 12-month high of GBX 1,777.18 ($23.24).
Insider Transactions at GSK
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading
- Five stocks we like better than GSK
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
- Winners And Losers In The Oilfield Supercycle
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
